For patients facing certain solid tumors, a positive scan can feel like a cruel reprieve. This gap, between diagnostic imaging and effective treatment, is the clinical and commercial space where Starget Pharma is placing its bet. The Israeli biotech is developing a class of drugs designed to be both the spotlight and the sniper, using proprietary peptides to deliver radioactive isotopes directly to cancer cells [Starget, Unknown].
With $38 million raised to date and a fresh $18 million Series A, the company is moving its lead candidate toward the clinic [Calcalist/CTech, 2026].
A Platform Built on Backbone Dynamics
Starget's technical wedge is its 'Backbone Dynamics' peptide platform. Starget's approach uses backbone-cyclized peptide chemistry, a method that locks the molecule into a stable, three-dimensional shape. This rigidity, combined with in-silico AI design tools, is intended to create radioligands with optimized binding to tumor-specific receptors [Starget, Unknown].
The platform is designed for a theranostic approach, meaning each program yields a matched pair: one compound for diagnostic imaging and another for therapeutic radiation delivery. The company's pipeline lists programs targeting receptors like CCK2R and GRPR [Starget, Unknown].
The Clinical Roadmap and U.S. Footprint
The Series A proceeds are earmarked for advancing Starget's pipeline into clinical development [Opportunity Louisiana, Feb 2026]. The lead program is a first-in-class theranostic pair targeting the SSTR3 receptor for potential use in sarcoma, neuroendocrine tumors (NETs), and malignant melanoma. A Phase 1b trial for a different, undisclosed peptide radioligand was previously supported by a $5.1 million investment from the Cancer Focus Fund [Starget Pharma, 2024].
A critical component of Starget's strategy is its manufacturing and translational partnership. The company has a strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) in Shreveport, Louisiana [Morningstar, Feb 2026]. This ties Starget's Israeli discovery engine to U.S.-based clinical production capabilities [Expansion Solutions, Feb 2026].
The Team and Investor Conviction
The founding team blends entrepreneurial and scientific expertise. CEO Sigal Kalmanson Cusnir leads the company, with co-founder Ronen Clemson bringing a track record that includes co-founding and serving on the board of Urogen Pharma Ltd. [Equilar ExecAtlas, Unknown]. Ronen Kalmanson is listed as chairman and co-founder [Crunchbase, Unknown]. Dr. Michel Afargan, with the title Head of Drug Development & Radiopharmaceutical Strategies, adds depth to the scientific leadership [LinkedIn, retrieved 2026].
Their progress has attracted specialized oncology investors. The recent $18 million Series A was led by Ilex Medical, with participation from existing backers the Louisiana Growth Fund and the Cancer Focus Fund [PR Newswire, Feb 2026].
Navigating a High-Stakes Landscape
The ambition is clear, but the path is lined with the inherent risks of drug development. Starget's platform enters a radiopharmaceutical field that has grown increasingly crowded and competitive. The company's differentiation rests on the specificity of its backbone-cyclized peptides and its AI-driven design cycle, claims that will be validated by clinical data.
Key near-term milestones are clinical. The capital is in place to advance multiple programs toward clinical entries planned for 2026 [Investing.com, Feb 2026]. Success will be measured in trial initiations, then in early clinical readouts on imaging quality, safety, and tumor response.